« Back
Home /
Eravacycline (dihydrochloride)

Eravacycline (dihydrochloride)

Item no.	HY-16980A-50mg
Manufacturer	MedChem Express
CASRN	1334714-66-7
Amount	50 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.88
Dry ice	Yes
Citations	[1]Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.\|[2]Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7).\|[3]Xiao XY, et al. Fluorocyclines: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605.\|[4]Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58.\|[5]Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. ACS Infect Dis. 2024 Dec 13;10(12):4127-4136. Biomaterials. 2024 Sep 11:314:122815. Cureus. 2024 Dec 1;16(12):e74917. J Antibiot (Tokyo). 2025 May;78(6):370-379. J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. mBio. 2021 Jun 29;12(3):e0103121. Microb Pathog. 2020 Dec;149:104502. Microbiol Spectr. 2025 Oct 16:e0160325. Pharmaceutics. 2021 Dec 5;13(12):2085. Research Square Preprint. 2022 Feb. Ann Lab Med. 2021 May 1;41(3):293-301. Antibiotics (Basel). 2022 Sep 23;11(10):1298. Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. Antimicrob Agents Chemother. 2021 May 18;65(6):e00203-21. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. Diagn Micr Infec Dis. 2020 Nov;98(3):115129. Infect Drug Resist. 2023 Apr 17:16:2271-2279. Infect Drug Resist. 2023 Sep 8:16:6005-6015. J Antibiot (Tokyo). 2019 Aug;72(8):600-604. J Antibiot (Tokyo). 2022 Sep;75(9):498-508. J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. J Clin Microbiol. 2020 Jan 28;58(2):e01603-19. Microbiol Spectr. 2023 Feb 14;11(1):e0323822. Microbiol Spectr. 2023 Jun 15;11(3):e0071823. Nat Microbiol. 2023 Mar;8(3):410-423. Nat Struct Mol Biol. 2023 Sep;30(9):1380-1392. Virulence. 2022 Dec;13(1):77-88.
Smiles	O=C(NC(C(O)=C1C2=O)=CC(F)=C1C[C@@]3([H])C[C@@]4([H])[C@H](N(C)C)C(O)=C(C(N)=O)C([C@@]4(O)C(O)=C32)=O)CN5CCCC5.[H]Cl.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	TP-434 dihydrochloride,TP-434-046
Shipping Condition	Dry ice
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Bacterial; Beta-lactamase
Manufacturer - HS Code	H361, H362
Shipping Temperature	Dry Ice
Storage Conditions	-80°C, protect from light, stored under nitrogen
Molecular Weight	631.48
Product Description	Eravacycline dihydrochloride (TP-434 dihydrochloride) is a potent and broad-spectrum antibacterial agent.
Manufacturer - Research Area	Infection
Solubility	DMSO : ≥ 50 mg/mL\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H361, H362

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.